Pravastatin Dosing in Chronic Kidney Disease
In patients with CKD and severe renal impairment (eGFR <30 mL/min/1.73 m²), start pravastatin at 10 mg once daily with a maximum dose of 40 mg daily; for mild-to-moderate CKD (eGFR ≥30 mL/min/1.73 m²), use standard dosing of 40-80 mg once daily. 1
Dosing Algorithm by CKD Stage
CKD Stage 3a-5 (eGFR <60 mL/min/1.73 m²) - NOT on Dialysis
For patients ≥50 years:
- Starting dose: 40 mg once daily for eGFR 30-60 mL/min/1.73 m² 1
- Starting dose: 10 mg once daily for eGFR <30 mL/min/1.73 m² (severe impairment) 1
- Maximum dose: 40 mg daily in severe renal impairment 1
- Guideline recommendation: Statin or statin/ezetimibe combination is strongly recommended (Grade 1A) 2, 3
The FDA label explicitly states that severe renal impairment requires dose reduction due to altered pharmacokinetics, though pravastatin has dual hepatic and renal elimination routes 1, 4.
CKD Stage 1-2 (eGFR ≥60 mL/min/1.73 m²)
For patients ≥50 years:
- Standard dosing: 40-80 mg once daily 1
- Guideline recommendation: Statin monotherapy strongly recommended (Grade 1B) 2, 3
- No dose adjustment needed 1
Patients on Hemodialysis
- Standard dosing: 20-40 mg once daily 5
- Hemodialysis contributes to pravastatin clearance (40-80 mL/min dialytic clearance), but no dose adjustment is necessary 5
- Timing relative to dialysis is not critical as pravastatin pharmacokinetics remain similar to healthy volunteers 5
Administration Details
- Timing: Once daily at any time, with or without food 1
- LDL-C monitoring: Assess as early as 4 weeks after initiation and adjust if needed 1
- Goal: Maximize absolute LDL-C reduction rather than targeting specific LDL-C levels 3
Drug Interactions Requiring Dose Modification
Critical adjustments:
- Cyclosporine: Start 10 mg daily, maximum 20 mg daily 1
- Clarithromycin or Erythromycin: Maximum 40 mg daily 1
- Bile acid sequestrants: Give pravastatin ≥1 hour before or ≥4 hours after 1
Monitoring Parameters
Essential monitoring:
- Baseline: eGFR, LDL-C, liver transaminases, creatine kinase if symptomatic
- Follow-up: LDL-C at 4 weeks, then as clinically indicated 1
- Renal function: Monitor eGFR periodically; pravastatin may stabilize or slightly improve eGFR in moderate CKD 6
- Muscle symptoms: Assess for myalgias, weakness (risk increased with renal impairment)
Key Clinical Considerations
Metabolite accumulation: The inactive metabolite SQ 31,945 accumulates in dialysis patients (accumulation index 1.7), but this is clinically insignificant 5. The parent drug and active metabolite (SQ 31,906) do not accumulate 5, 4.
Cardiovascular benefit in CKD: Pravastatin reduces CHD by 48%, stroke by 73%, and total mortality by 51% in moderate CKD patients 6. The absolute benefit is larger in CKD due to higher baseline cardiovascular risk 2.
Common pitfall: Do not withhold statins in CKD patients ≥50 years based on LDL-C levels—age and eGFR alone justify treatment 2, 3. The 10-year coronary risk exceeds 10% in this population regardless of cholesterol levels.
Alternative if inadequate response: If LDL-C goals are not achieved with pravastatin 80 mg daily, switch to a high-intensity statin or add ezetimibe rather than exceeding maximum pravastatin dose 1.